Quarterly Report (10-q)

Date : 08/20/2018 @ 7:55PM
Source : Edgar (US Regulatory)
Stock : Vystar Corp. (QB) (VYST)
Quote : 0.0244  -0.00039 (-1.57%) @ 8:31PM

Quarterly Report (10-q)

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2018

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______________ to ________________

 

Commission File Number 000-53754

 

 

 

VYSTAR CORPORATION

(Exact Name of Registrant as Specified in its Charter)

 

Georgia 20-2027731

(State or other jurisdiction of

incorporation or organization)

(IRS Employer

Identification No.)

 

101 Aylesbury Rd

Worcester, MA 01609

 

 (Address of Principal Executive Offices, Zip Code)

 

(508) 791-9114

 

(Registrant’s telephone number including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  

YES ☒   NO  ☐

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES ☒   NO ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer ☐ Smaller reporting company ☒
(Do not check if a smaller reporting company) Emerging growth company ☐

 

Indicate by check mark whether the registrant is a shell Company (as defined in Rule 12b-2 of the Exchange Act.)  YES ☐ NO ☒

 

As of August 17, 2018, there were 250,633,072 shares of the Registrant’s common stock, par value $0.0001 per share, outstanding.

 

 

 

     
     

 

INFORMATION RELATING TO FORWARD-LOOKING STATEMENTS

 

In addition to historical information, this Form 10-Q contains statements relating to our future results (including certain projections and business trends) that are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and are subject to the “safe harbor” created by those sections. The following discussion of the financial condition and results of operations of the Company should be read in conjunction with the financial statements and the related notes thereto included in this Quarterly Report on Form 10-Q (this “Report”). This Report contains certain forward-looking statements and the Company’s future operating results could differ materially from those discussed herein. Our disclosure and analysis included in this Report concerning our operations, cash flows and financial position, including, in particular, the likelihood of our success in expanding our business and raising debt and capital securities include forward-looking statements. Statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as “expect”, “anticipate”, “intend”, “plan”, “believe”, “estimate”, “may”, “project”, “will likely result”, and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are subject to certain risks, uncertainties, and assumptions, including prevailing market conditions and are more fully described under “Part I, Item 1A – Risk Factors” of our Form 10-K for the year ended December 31, 2017. New risks and uncertainties arise from time to time, and it is impossible for us to predict these events or how they may affect us. In any event, these and other crucial factors, including those set forth in Item 1A – “Risk Factors” of our Form 10-K for the year ended December 31, 2017 may cause actual results to differ materially from those indicated by our forward-looking statements.

 

Although we believe that these statements are based upon reasonable assumptions, we cannot guarantee future results and readers are cautioned not to place undue reliance on these forward-looking statements, which reflect management’s opinions only as of the date of this filing. There can be no assurance that (i) we have correctly measured or identified all of the factors affecting our business or the extent of these factors’ likely impact, (ii) the available information with respect to these factors on which such analysis is based is complete or accurate, (iii) such analysis is correct or (iv) our strategy, which is based in part on this analysis, will be successful. The Company undertakes no obligation to update or revise forward-looking statements.

 

All references to “we”, “us”, “our”, “Vystar”, or “Kiron” in this Quarterly Report on Form 10-Q mean Vystar Corporation, and affiliates.

 

  2  
 

 

Vystar Corporation

Form 10-Q for the Quarter Ended June 30, 2018

 

Index

 

Part I.  Financial Information

  4
       
Item 1. Financial Statements   4
  Balance Sheets at June 30, 2018 (unaudited) and December 31, 2017   4
  Statements of Operations for the Three and Six Months Ended June 30, 2018 (unaudited) and 2017 (unaudited)   5
  Statements of Cash Flows for the Six Months Ended June 30, 2018 (unaudited) and 2017 (unaudited)   6
  Notes to Financial Statements (unaudited)   7
       
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations   20
       
Item 3. Quantitative and Qualitative Disclosures About Market Risk   25
       
Item 4. Controls and Procedures   26
     
Part II.  Other Information   27
       
Item 1. Legal Proceedings   27
       
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds   27
       
Item 3. Defaults Upon Senior Securities   27
       
Item 4. Mine Safety Disclosures   28
       
Item 5. Other Information   28
       
Item 6. Exhibits   28
     
SIGNATURES   29

 

  3  
 

 

Part I. FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

VYSTAR CORPORATION
CONDENSED BALANCE SHEETS

 

    June 30,     December 31,  
    2018     2017  
      (unaudited)          
ASSETS                
Current assets:                
Cash   $ 414,363     $ 13,502  
Accounts receivable     9,354       3,963  
Inventories     507,897        
Prepaid expenses     130,172       166,091  
Total current assets     1,061,786       183,556  
Property and equipment, net     314,606        
Other assets:                
Intangible assets, net     2,295,102       123,882  
Total assets   $ 3,671,494     $ 307,438  
LIABILITIES AND STOCKHOLDERS’ DEFICIT                
Current liabilities:                
Related party line of credit   $     $ 1,499,875  
Accounts payable     540,576       468,906  
Accrued stock based compensation     360,525       19,355  
Shareholder and contingently convertible notes payable - current maturities     100,000       674,990  
Accrued expenses and interest payable     181,892       294,995  
Total current liabilities     1,182,993       2,958,121  
Long-term liabilities:                
Loan payable Fidelity Bank     500,000        
Related party loan     1,499,875        
Shareholder and contingently convertible notes payable - net of current maturities     613,519       206,683  
Total long-term liabilities     2,613,394       206,683  
Total liabilities     3,796,387       3,164,804  
                 
Stockholders’ deficit:                
Preferred stock, $0.0001 par value 15,000,000 shares authorized;
13,828 issued and outstanding at June 30, 2018 and December 31, 2017, respectively
    1       1  
Common stock, $0.0001 par value, 600,000,000 shares authorized;
235,633,072 and 132,809,218 shares issued and outstanding at June 30, 2018 and
December 31, 2017, respectively
    23,563       13,280  
Additional paid-in capital     30,125,630       25,128,476  
Accumulated deficit     (30,274,087 )     (27,999,123 )
Total stockholders’ deficit     (124,893 )     (2,857,366 )
Total liabilities and stockholders’ deficit   $ 3,671,494     $ 307,438  

 

The accompanying notes are an integral part of these financial statements.

 

  4  
 

 

VYSTAR CORPORATION
CONDENSED STATEMENTS OF OPERATIONS
(Unaudited)

 

    Three Months Ended     Six Months Ended  
    June 30,     June 30,  
    2018     2017     2018     2017  
Revenue   $ 59,029     $ 3,087     $ 62,973     $ 6,323  
                                 
Cost of revenue     19,044       6,610       68,465       10,220  
                                 
Gross profit (loss)     39,985       (3,523 )     (5,492 )     (3,897 )
                                 
Operating expenses:                                
General and administrative, including non-cash share-based compensation of $185,204 and $32,977 for the three months ended June 30, 2018 and 2017, respectively and $1,611,911 and $214,502 for the six months ended June 30, 2018 and 2017, respectively.     729,510       255,811       2,492,959       536,592  
Total operating expenses     729,510       255,811       2,492,959       536,592  
                                 
Loss from operations     (689,525 )     (259,334 )     (2,498,451 )     (540,489 )
                                 
Other income (expense):                                
Other income     326,237             326,237        
Interest (expense)     (61,302 )     (42,728 )     (102,750 )     (85,271 )
                                 
Total other income (expense), net     264,935       (42,728 )     223,487       (85,271 )
                                 
Net loss   $ (424,590 )   $ (302,062 )   $ (2,274,964 )   $ (625,760 )
                                 
Basic and diluted loss per share:                                
Net loss per share   $ (0.00 )   $ (0.00 )   $ (0.00 )   $ (0.00 )
                                 
Basic and diluted weighted average number of common shares outstanding     171,550,328       119,854,369       171,765,798       119,854,369  

 

The accompanying notes are an integral part of these financial statements.

 

  5  
 

 

VYSTAR CORPORATION
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)

 

    Six Months Ended  
    June 30,  
    2018     2017  
Cash flows from operating activities:                
Net loss   $ (2,274,964 )   $ (625,760 )
Adjustments to reconcile net loss to cash used in operating activities:                
Share-based compensation     1,611,911       214,502  
Allowance for uncollectible accounts receivable            
Depreciation     26,394        
Amortization of intangible assets     55,791       7,840  
(Increase) decrease in assets:                
Accounts receivable     (5,391 )     15,589  
Inventories     (304,306 )      
Prepaid expenses     43,419       2,434  
Increase (decrease) in liabilities:                
Accounts payable     71,670       4,336  
Accrued compensation and expenses     81,287       36,331  
Net cash used in operating activities     (694,189 )     (344,728 )
                 
Cash flows from financing activities:                
Proceeds of Fidelity Bank loan     500,000        
Issuance of common stock, net of costs           374,500  
Proceeds from the issuance of notes, net     595,050        
Net cash provided by financing activities     1,095,050       374,500  
                 
Net increase in cash     400,861       29,772  
Cash - beginning of period     13,502       36,282  
Cash - end of period   $ 414,363     $ 66,054  
                 
Cash paid during the period for:                
Interest   $ 59,568     $ 48,023  
                 
Non-cash transactions:                
Purchase of tangible and intangible assets   $ 2,786,602     $  
Shareholder Notes Converted to Common Stock     784,173       55,470  
Shares issued for accrued compensation     1,125,000        
Total non-cash transactions   $ 4,695,775     $ 55,470  

 

The accompanying notes are an integral part of these financial statements.

 

  6  
 

 

VYSTAR CORPORATION

NOTES TO FINANCIAL STATEMENTS

 

NOTE 1 DESCRIPTION OF BUSINESS

 

Vystar Corporation (“Vystar”, the “company”, “we”, “us”, or “our”) is the creator and exclusive owner of the innovative technology to produce Vytex® Natural Rubber Latex (“NRL”). Our global multi-patented technology reduces antigenic and total protein in natural rubber latex products to virtually undetectable levels. Vytex® NRL, our “ultra-low protein” natural rubber latex has been introduced throughout the worldwide marketplace that uses NRL or latex substitutes as a raw material for end products. Natural rubber latex or latex substitutes are used in an extensive range of products including balloons, textiles, footwear and clothing (threads), adhesives, foams (mattresses, pillows, mattress toppers, etc.), furniture (foam and adhesives), carpet, paints, coatings, protective equipment, sporting equipment, and, especially health care products such as condoms, surgical and exam gloves, among others.

 

Vystar has expanded into the consumer arena with an introduction into mattresses, mattress toppers and pillows aligning with key foam manufacturers, mattresses, toppers, pillow producers, and furniture stores in specific areas of the Unites States. On January 22, 2015, Vystar announced the signing of an exclusive domestic distribution agreement with Worcester, MA based NHS Holdings, LLC (NHS) who sources eco-friendly materials and technologies for use in furnishings and other markets. In September 2016, the Vystar Board of Directors voted to end the January 2015 NHS agreement and replace it with a global exclusive for foam manufactured with Vytex and sold into the home furnishings industry. This change reflects the global nature of the mattress, topper and pillow businesses, the need for local warehousing, and access to container loads of foam cores and pillows for domestic, European and Asian manufacturers. As of April 18, 2018 Vystar reacquired its distribution rights from NHS and purchased NHS’s inventory and related assets and began selling and distributing the Vytex® NRL products itself. (See Note 9)

 

NOTE 2 BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Basis of Presentation

 

The accompanying unaudited condensed financial statements (“the financial statements”) have been prepared in accordance with generally accepted accounting principles of the United States of America (“GAAP”) for interim financial information. Accordingly, certain information and footnotes required by GAAP for complete financial statements may be condensed or omitted.  These interim financial statements should be read in conjunction with our audited financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2017, filed with the Securities and Exchange Commission (“SEC”).  In the opinion of Vystar management, these financial statements contain all adjustments (which comprise only normal and recurring accruals) necessary to present fairly the financial position and results of operations as of and for the periods ended June 30, 2018 and 2017.

 

Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying disclosures. Although these estimates are based on management’s knowledge of current events and actions the Company may undertake in the future, actual results could differ from these estimates. Examples include valuation allowances for valuation of intangible assets acquired, realization and valuation of inventories and fair values of share-based compensation.

 

  7  
 

 

Concentration of Credit Risk

 

Certain financial instruments potentially subject the Company to concentrations of credit risk. These financial instruments consist primarily of cash and accounts receivable. Cash held in banks in many cases exceeds the Federal Deposit Insurance Corporation, or FDIC, insurance limits. While we monitor our cash balances on a regular basis and adjust the balances as appropriate, these balances could be impacted if the underlying financial institutions fail. To date, we have experienced no loss or lack of access to our cash; however, we can provide no assurances that access to our cash will not be impacted by adverse conditions in the financial markets.

 

Loss Per Share

 

Because the Company reported a net loss for the six-month periods ended June 30, 2018 and 2017, common stock equivalents, including stock options and warrants, were anti-dilutive; therefore, the amounts reported for basic and diluted loss per share were the same. Excluded from the computation of diluted loss per share were options outstanding to purchase 7,298,271 shares and 9,718,271 shares of common stock for the six months ended June 30, 2018 and 2017, respectively, as their effect would be anti-dilutive. Warrants to purchase 14,861,924 and 18,084,609 shares of common stock for the six months ended June 30, 2018 and 2017, respectively, were also excluded from the computation of diluted loss per share as their effect would be anti-dilutive.

 

Acquisition of Assets

 

Amounts paid for acquisitions are allocated to the assets acquired and liabilities assumed based on their estimated fair value at the date of acquisition. The fair value of identifiable intangible assets is based on valuations that use information and assumptions provided by management. Identifiable intangible assets with finite lives are amortized over their useful lives. Acquisition-related costs, including, legal, accounting, and other costs, are expensed in the periods in which the costs are incurred. The results of operations of acquired assets are included in the financial statements from the acquisition date.

 

Inventories

 

Inventory cost includes those costs directly attributable to the product before sale. Inventory consists of foam slabs and is carried at the lower of cost or market (net realizable value), using first-in, first-out method. As of June 30, 2018, the Company had approximately $508,000 in finished goods inventory. At December 31, 2017 there was no inventory .

 

Property and Equipment

 

Property and equipment is recorded at cost. Depreciation is computed using the straight-line method over the estimated useful lives of the assets ranging from three to seven years.

 

Revenues

 

Revenue Recognition

 

On January 1, 2018, we adopted FASB Accounting Standards Codification (“ASC”) Topic 606,  Revenue from Contracts with Customers  (“ASC 606”) The new guidance sets forth a new five-step revenue recognition model which replaces the prior revenue recognition guidance in its entirety and is intended to eliminate numerous industry-specific pieces of revenue recognition guidance that have historically existed in U.S. GAAP. The underlying principle of the new standard is that a business or other organization will recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects what it expects to receive in exchange for the goods or services. The standard also requires more detailed disclosures and provides additional guidance for transactions that were not addressed completely in the prior accounting guidance.

 

  8  
 

 

We reviewed all contracts at the date of initial application and elected to use the modified retrospective transition method, where the cumulative effect of the initial application is recognized as an adjustment to opening retained earnings at January 1, 2018. Therefore, comparative prior periods have not been adjusted and continue to be reported under FASB ASC Topic 605, Revenue Recognition , (“ASC 605”). The adoption of the new revenue recognition guidance was immaterial to our condensed statements of operations, balance sheet, and cash flows as of and for the six months ended June 30, 2018.

 

Our principal activities from which we generate our revenue are product sales.

 

Revenue is measured based on consideration specified in a contract with a customer. A contract with a customer exists when we enter into an enforceable contract with a customer. The contract is based on either the acceptance of standard terms and conditions on the websites for e-commerce customers and via telephone with our third-party call center for our print media and direct mail customers, or the execution of terms and conditions contracts with retailers and wholesalers. These contracts define each party’s rights, payment terms and other contractual terms and conditions of the sale. Consideration is typically paid prior to shipment via credit card or check when our products are sold direct to consumers or approximately 30 days from the time control is transferred when sold to wholesalers, distributors and retailers. We apply judgment in determining the customer’s ability and intention to pay, which is based on a variety of factors including the customer’s historical payment experience and, in some circumstances, published credit and financial information pertaining to the customer.

 

A performance obligation is a promise in a contract to transfer a distinct product to the customer, which for us is transfer of finished goodss to our customers. Performance obligations promised in a contract are identified based on the goods that will be transferred to the customer that are both capable of being distinct and are distinct in the context of the contract, whereby the transfer of the goods is separately identifiable from other promises in the contract. We have concluded the sale of finished goods and related shipping and handling are accounted for as the single performance obligation.

 

The transaction price of a contract is allocated to each distinct performance obligation and recognized as revenue when or as the customer receives the benefit of the performance obligation. The transaction price is determined based on the consideration to which we will be entitled to receive in exchange for transferring goods to the customer. We issue refunds to e-commerce and print media customers, upon request, within 30 days of delivery. We estimate the amount of potential refunds at each reporting period using a portfolio approach of historical data, adjusted for changes in expected customer experience, including seasonality and changes in economic factors. For retailers, distributors and wholesalers, we do not offer a right of return or refund and revenue is recognized at the time products are shipped to customers. In all cases, judgment is required in estimating these reserves. Actual claims for returns could be materially different from the estimates. The were no estimated reserve for sales returns and allowances at June 30, 2018 and December 31, 2017, respectively.

 

We recognize revenue when we satisfy a performance obligation in a contract by transferring control over a product to a customer when product is shipped. Taxes assessed by a governmental authority that are both imposed on and concurrent with a specific revenue-producing transaction, that are collected by us from a customer, are excluded from revenue. Shipping and handling costs associated with outbound freight after control over a product has transferred to a customer are accounted for as a fulfillment cost and are included in cost of product sales.

 

Advertising Costs

 

Advertising costs are expensed as incurred. Included in general and administrative expenses is approximately $33,000 and $11,000 for the six months ended June 30, 2018 and 2017, respectively.

 

  9  
 

 

Fair Value of Financial Instruments

 

The Company’s financial instruments consist of cash, accounts receivable, accounts payable, accrued expenses, line of credit and shareholder notes payable.  The carrying values of all the Company’s financial instruments approximate fair value because of their short maturities. In addition to the short maturities, the carrying amounts of our line of credit and shareholder notes payable approximate fair value because the interest rates at June 30, 2018 approximate market interest rates for the respective borrowings.

 

In specific circumstances, certain assets and liabilities are reported or disclosed at fair value.  Fair value is the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date in the Company’s principal market for such transactions.  If there is not an established principal market, fair value is derived from the most advantageous market.

 

Valuation inputs are classified in the following hierarchy:

 

Level 1 inputs are unadjusted quoted prices in active markets for identical assets or liabilities.
   
Level 2 inputs are directly or indirectly observable valuation inputs for the asset or liability, excluding Level 1 inputs.
   
Level 3 inputs are unobservable inputs for the asset or liability.

 

Highest priority is given to Level 1 inputs and the lowest priority to Level 3 inputs.  Acceptable valuation techniques include the market approach, income approach, and cost approach.  In some cases, more than one valuation technique is used.

 

Recent Accounting Pronouncements

 

In July 2017, the FASB issued ASU 2017-11, Earnings per share (Topic 260), Distinguishing Liabilitits from Equity (Topic 480), and Derivatives and Hedging (Topic 815): Accounting for Certain Financial Instruments with Down Round Features . The update addresses the complexity of accounting for certain financial instruments with down round features and the liability or equity classification of financial instruments with warrants or convertible features. The guidance eliminates the requirement to consider “down round” features when determining whether certain equity-linked financial instruments or embedded features are indexed to an entity’s own stock. Our warrants issued with our convertible notes are treated as derivative instruments, because they include a “down round” feature. The ASU is effective for annual periods beginning after December 15, 2018, and for interim periods within those years, with early adoption permitted. We do not expect this ASU to have a significant impact on our condensed financial statements and related disclosures .

 

In January 2017, the FASB issued ASU 2017-01,  Business Combinations (Topic 805): Clarifying the Definition of a Business . The update provides that when substantially all the fair value of the assets acquired is concentrated in a single identifiable asset or a group of similar identifiable assets, the set is not a business. This update is effective for annual and interim periods beginning after December 15, 2017, and interim periods within that reporting period. We adopted this ASU on January 1, 2018 and the impact on our financial statements will depend on the facts and circumstances of any specific future transactions.

 

In June 2018, the FASB issued ASU 2018-07, Compensation - Stock Compensation (Topic 718) to expand the scope of ASC 718, Compensation - Stock Compensation (Topic 718) ( ASU 2018-07 ), to include share-based payment transactions for acquiring goods and services from non-employees. The pronouncement is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2018, with early adoption permitted. We do not expect this ASU to have a significant impact on our condensed consolidated financial statements and related disclosures.

 

 

  10  
 

 

NOTE 3 LIQUIDITY AND GOING CONCERN

 

The Company’s financial statements are prepared using the accrual method of accounting in accordance with GAAP and have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business.  However, the Company has incurred significant losses and experienced negative cash flow since its inception.  At June 30, 2018, the Company had cash of $414,000 and a deficit in working capital of approximately $125,000.  Further, at June 30, 2018, the accumulated deficit amounted to approximately $30 million.  As a result of the Company’s history of losses and financial condition, there is substantial doubt about the ability of the Company to continue as a going concern.

 

A successful transition to attaining profitable operations is dependent upon obtaining sufficient revenues from our recent acquisitions in the second quarter of 2018 and financing to fund the Company’s planned expenses and achieving a level of revenue adequate to support the Company’s cost structure. Management plans to finance future operations through the use of cash on hand, increased revenue from the sale of Vytex NRL products, Vytex division license fees, our credit facility, stock warrant exercises from existing shareholders, raising capital through private placements of capital stock and debt.

 

The Company’s future expenditures will depend on numerous factors, including: the rate at which the Company can introduce and license Vytex NRL to manufacturers; the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; market acceptance of the Company’s products and services; revenue from the sale of Vytex NRL products; and competing technological developments. As the Company expands its activities and operations, cash requirements are expected to increase at a rate consistent with revenue growth after the Company has achieved sustained revenue generation.

 

There can be no assurances that the Company will be able to achieve its projected level of revenue in 2018 and beyond. If the Company is unable to achieve its projected revenue and is not able to obtain alternate additional financing of equity or debt, the Company would need to significantly reorient its operations during 2018, which could have a material adverse effect on the Company’s ability to achieve its business objectives and as a result may require the Company to file for bankruptcy or cease operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions.

 

NOTE 4 PROPERTY AND EQUIPMENT

 

Property and equipment, net consists of:

 

    June 30,     December 31,  
    2018     2017  
Tooling & testing equipment   $ 319,000     $  
Warehouse equipment     22,000        
Furniture and fixtures     8,522       8,522  
      349,522       8,522  
Accumulated depreciation     (34,916 )     (8,522 )
Property and equipment, net   $ 314,606     $  

 

Depreciation for the six months ended June 30, 2018 was $26,394. There was no depreciation for the six months ended June 30, 2017.

 

  11  
 

 

NOTE 5 INTANGIBLE ASSETS

 

Intangible consists of the following as of June 30, 2018:

 

          Accumulated           Estimated Life  
    Gross     Amortization     Net     (in years)  
Customer relationships   $ 250,000     $ 10,417     $ 239,583       5  
Reacquired distribution rights     481,341             481,341          
Website     156,000       4,875       151,125       4  
FDA Certification     650,000       16,250       633,750       5  
Patents     438,551       135,521       303,030       6  
Drawings, mechanical engineering and software     214,670       5,367       209,303       5  
Tradename and brand     284,072       7,102       276,970       5  
Intangible Assets, net   $ 2,474,634     $ 179,532     $ 2,295,102          

 

Patents represent legal and other fees associated with the registration of patents. The Company has multiple patents with the United States Patent and Trade Office (USPTO), as well as many international PCT (Patent Cooperation Treaty) patents.

 

Amortization expense for the six months ended June 30, 2018 and 2017 was $55,791 and $7,840, respectively.

 

Estimated future amortization expense for finite-lived intangible assets is as follows:

 

    2019   2020   2021   2022   2023   Thereafter  
Intangible assets   $ 365,947   $ 365,947   $ 365,947   $ 361,072   $ 288,038   $ 66,810  

 

NOTE 6 NOTES PAYABLE AND LOAN FACILITY

 

Related Party Line Loan (CMA Note Payable)

 

On November, 2, 2012, the Company executed a note with CMA Investments, LLC, a related party and a Georgia limited liability company (“CMA”), a line of credit with a principal amount of $1,500,000 (the “CMA Note”). CMA is a limited liability company of which three of the directors of the Company (“CMA directors”) were initially the members. Pursuant to the terms of the CMA Note, interest is computed at LIBOR plus 5.25% (8.22% at June 30, 2018), on amounts drawn and fees. The weighted average interest rate in effect on the borrowings for the six months ended June 30, 2018 was 7.15%. There are no available borrowings under the CMA note at June 30, 2018. The Company entered into a settlement agreement with CMA Investments, LLC in July 2018 (see note 11).

 

During the six months ended June 30, 2018, the Company recorded approximately $120,000 of interest expense and at June 30, 2018, had approximately $20,000 accrued on the CMA note.

 

  12  
 

 

Fidelity Bank Note Payable

 

During the six months ended June 30, 2018 certain investors have guaranteed $100,000 each with Fidelity Bank to establish a $500,000 revolving line of credit with Fidelity Bank. At the present time, the Company is paying interest only at a rate of 4.5% per annum, with a balloon payment of $500,000 due in 2033.

 

Shareholder and Contingent Convertible Notes Payable

 

The following table summarizes the shareholder and contingent convertible notes payable:

 

    June 30,     December 31,  
    2018     2017  
Shareholder and contingent convertible notes   $ 732,563     $ 881,673  
Accrued interest     18,260       294,995  
Total notes and accrued interest     750,823       1,176,668  
                 
Less - Debt discount     (19,044 )      
 - Accrued interest     (18,260 )     (294,995 )
 - Current maturities     (100,000 )     (674,990 )
                 
Total long-term debt   $ 613,519     $ 206,683  

 

From January 1, 2018 and through the date of these financial statements, the Company has issued certain contingent convertible promissory notes in varying amounts, in the aggregate of $466,500. The face amount of the notes represents the amount due at maturity along with the accrued interest, at which time that amount may be converted into shares of the Company stock based on the lowest 2 day closing price for the trailing 20 days prior to conversion and carrying a 35% discount. The contingent convertible notes provide for interest to accrue at an interest rate equal to 12% per annum or the maximum rate permitted under applicable law after the occurrence of any event of default as provided in the notes. At any time after 180 days from the issue date, the holder, at its option, may convert the outstanding principal balance and accrued interest into shares of common stock of the Company. The initial conversion price for the principal and interest in connection with voluntary conversions by a holder of the Convertible Notes ranges from $0.05 to $0.08 per share, subject to adjustment as provided therein. If the total outstanding balance of the contingent convertible notes were convertible as of June 30, 2018, they would have been convertible into approximately 27 million shares of the Company’s common stock. No derivative liability has been recorded as of June 30, 2018, as conversion is contingent. On the 180 th day, the conversion feature will be a derivative and recorded as interest expense.

 

In connection with the issuance of one of the contingent convertible notes, the Company issued a warrant to purchase 286,875 shares of the Company’s common stock. The exercise term of the warrant is at any time on or after the six (6) month anniversary or prior to the five (5) year anniversary of the related note (February 2023). The exercise price of the warrant is $0.40 per share of the Company’s common stock, as may be adjusted from time to time pursuant to the antidilution provisions of the related warrant. Pursuant to ASU 2017-11, such antidilution features do not subject the Company to derivative accounting pursuant to ASC815.

 

Other than the contingent convertible notes disclosed above, such notes are (i) unsecured, (ii) bear interest at an annual rate ranging from five percent (5%) to twelve percent (12%) per annum, and (iii) are contingently convertible at the Company’s option based on potential future events into shares of common stock. During the quarter ended June 30, 2018 approximately $1,134,000 of these notes and accrued interest were converted to approximately 22,686,000 shares of common stock resulting in a gain of approximately $340,000 of which approximately $203,000 was from related parties and has been recorded as additional paid-in capital.

 

  13  
 

 

NOTE 7 STOCKHOLDERS’ EQUITY

 

Common Stock and Warrants  

 

On June 30, 2016, the Company issued 997,466 common shares as compensation under the Company’s Business Development Agreement with Blue Oar Consulting, Inc. executed in March 2013 as amended in August 2013, as amended in February 2014, as amended in June 2016. On April 27, 2018, 7,500,000 shares were issued under the same agreement, as amended January 3, 2018. The Company recorded an expense of $375,000 for these shares. In addition, the Company accrued approximately $150,000, which approximates the fair value of the additional common stock compensation earned during 2018, included in the terms of the agreement, on the measured dates (included in accrued stock based compensation on the condensed balance sheet). This agreement will remain in force unless terminated by either party after twelve months from the date of the agreement, upon thirty days prior written notice to the other party. Also, $175,000 has been recorded in accounts payable for back-pay due to Blue Oar as of December 31, 2017.

 

On April 27, 2018, the Company issued 300,000 common shares as compensation under the Company’s Business Development Agreement with Designcenters.com with an effective date of January 3, 2018. The Company recorded an expense of $15,000 for these shares. In addition, the Company accrued approximately $110,500, which approximates the fair value of the additional common stock compensation, included in the terms of the agreement, on the measured dates (included in accrued stock based compensation on the condensed balance sheet). The terms of this agreement will remain in force unless terminated by either party after six months from the effective date, upon thirty days prior written notice to the other party.

 

On April 27, 2018, the Company issued 11,000,000 common shares as a signing bonus under an employment agreement to the CEO Steven Rotman with an effective date of January 3, 2018. The Company recorded an expense of $385,000 for these shares.

 

On April 27, 2018, the Company issued 3,721,408 common shares as compensation under the Company’s Business Development Agreement with Anchor Group, LLC with an effective date of January 3, 2018. The Company recorded an expense of $165,000 for these shares. In addition the Company accrued approximately $120,000, which approximates the fair value of the additional common stock, included in the terms of the agreement, on the measured dates (included in accrued stock based compensation on the condensed balance sheet). The terms of this agreement will remain in force unless terminated by either party after six months from the effective date, upon thirty days prior written notice to the other party.

 

From January 1, 2018 to February 9, 2018, the Company issued Convertible Promissory Notes (the “Notes”) for contract work performed by other entities, and in lieu of salary and expense reimbursement in the amount of $195,635. The Notes are (i) unsecured, (ii) bear interest at an annual rate of five percent (5%) per annum from date of issuance, and (iii) are convertible by the Company post April 19, 2018. The Notes mature one year from issuance but may be extended one (1) additional year by the Company. If converted, the Notes plus accrued interest are convertible into shares of the Company’s common stock at the prior twenty (20) day average closing price with a 50% discount.

 

  14  
 

 

In addition the following notes are convertible after six months from the issue date:

 

    Face     Interest           Net Cash  
Issue Date and Name   Amount     Rate     Maturity     Proceeds  
Jan 29, 2018 EMA   $ 80,000       12 %     Jan 29, 2019     $ 72,300  
Feb 14, 2018 Auctus     80,000       12 %     Nov 14, 2018       72,500  
Feb 13, 2018 FirstFire Global     76,500       5 %     Nov 13, 2018       72,500  
Feb 14, 2018 Power Up     85,000       12 %     Feb 14, 2019       82,000  
May 23, 2018 Power Up     83,000       12 %     May 23, 2019       80,000  
Jun 25, 2018 Power Up     68,000       12 %     Jun 25, 2019       65,000  

 

As of August 17, 2018, neither EMA, Auctus or FirstFire have chosen to enact their choice to convert their debt to stock.

 

On February 5, 2018, the Company issued 1,500,000 shares under the terms of a Consulting Agreement dated January 26, 2018 to STILLH20s Financial, LLC. The shares were valued at $150,000 (based on the value of the shares on the measurement date and expensed during the three months ended March 31, 2018).

 

On April 9, 2018, the Company issued 428,571 shares under the terms of a Consulting Agreement dated April 9, 2018 to vSource1 Capital Corporation. The shares were valued at $15,000 (based on the value of the shares on the measurement date and expensed during the three months ended June 30, 2018).

 

Cumulative Convertible Preferred Stock

 

On May 2, 2013, the Company began a private placement offering to sell up to 200,000 shares of the Company’s 10% Series A Cumulative Convertible Preferred Stock. Under the terms of the offering, the Company offered to sell up to 200,000 shares of preferred stock at $10.00 per share for a value of $2,000,000. The preferred stock accumulates a 10% per annum dividend and was convertible at a conversion price of $0.075 per common share at the option of the holder after a nine-month holding period. The conversion price was lowered to $0.05 per common share for those holders who invested an additional $25,000 or more in the Company’s common stock in the aforementioned September 2014 Private Placement. The preferred shares have full voting rights as if converted and have a fully participating liquidation preference.

 

At June 30, 2018, the 13,828 shares of outstanding preferred stock had accumulated undeclared dividends of approximately $70,476 and could be converted into 4,175,121 shares of common stock, at the option of the holder.

 

At December 31, 2017, the 13,828 shares of outstanding preferred stock had accumulated undeclared dividends of approximately $63,600 and could be converted into 4,037,977 shares of common stock, at the option of the holder.

 

NOTE 8 SHARE-BASED COMPENSATION

 

GAAP requires share-based payments to employees, including grants of employee stock options, warrants, and common stock to be recognized in the income statement based on their fair values at the date of grant, net of estimated forfeitures.

 

In total, the Company recorded $1,611,911 and $214,502 of stock-based compensation expense for the six-month period ended June 30, 2018 and 2017, respectively, including shares to be issued related to employee and board member stock options and common stock and warrants issued to non-employees.  As of June 30, 2018, $135,000 of unrecognized compensation expense related to non-vested share-based awards remains to be recognized over a period of approximately four years.

 

  15  
 

 

Options and Warrants

 

The Company used the Black-Scholes option pricing model to estimate the grant-date fair value of option and warrant awards granted. The following assumptions were used for warrant awards during the six months ended June 30, 2018:

 

Expected Dividend Yield – because we do not currently pay dividends, the expected dividend yield is zero;

 

Expected Volatility in Stock Price – volatility based on our own trading activity was used to determine expected volatility;

 

Risk-free Interest Rate – reflects the average rate on a United States Treasury Bond with a maturity equal to the expected term of the option; and

 

Expected Life of Award – because we have minimal experience with the exercise of options or warrants for use in determining the expected life of each award, we used the option or warrant’s contractual term as the expected life.

 

Options

 

During 2004, the Board of Directors of the Company adopted a stock option plan (the “Plan”) and authorized up to 4,000,000 shares to be issued under the Plan. In April 2009, the Company’s Board of Directors authorized an increase in the number of shares to be issued under the Plan to 10,000,000 shares and to include the independent Board Members in the Plan in lieu of continuing the previous practice of granting warrants each quarter to independent Board Members for services. At June 30, 2018, there were 2,251,729 shares of common stock available for issuance under the Plan. In 2014, the Board adopted an additional stock option plan which provides for an additional 5,000,000 shares which are all available as of June 30, 2018. The Plan is intended to permit stock options granted to employees to qualify as incentive stock options under Section 422 of the Internal Revenue Code of 1986, as amended (“Incentive Stock Options”). All options granted under the Plan that are not intended to qualify as Incentive Stock Options are deemed to be non-qualified options. Stock options are granted at an exercise price equal to the fair market value of the Company’s common stock on the date of grant, typically vest over periods up to 4 years and are typically exercisable up to 10 years.

 

There were no options granted during the six-month period ended June 30, 2018. The following table summarizes all stock option activity of the Company for the period.

 

    Number
of Shares
    Weighted
Average
Exercise Price
    Weighted Average
Contractual Life
(Years)
 
Outstanding, December 31, 2017     7,748,271     $ 0.16       4.43  
                         
Granted                      
                         
Exercised                      
                         
Expired     450,000     $ 0.68          
                         
Outstanding, June 30, 2018     7,298,271     $ 0.13       4.10  
                         
Exercisable, June 30, 2018     5,383,271     $ 0.19       5.29  

 

The aggregate intrinsic value of the options outstanding at June 30, 2018 were approximately $2,000. 

 

  16  
 

 

Warrants

 

Warrants are issued to employees for expenses and for compensation in lieu of cash as well as to third parties as payment for services and in conjunction with the issuance of common stock. The fair value of each common stock warrant issued for services is estimated on the date of grant using the Black-Scholes option pricing model.

 

The following table represents the Company’s warrant activity for the six months ended June 30, 2018:

 

      Number
of Shares
    Weighted
Average
Grant Date
Fair Value
    Weighted
Average
Exercise
Price
    Weighted
Average
Remaining
Contractual
Life
(Years)
 
Outstanding, December 31, 2017       14,699,582             $ 0.10       6.10  
                                   
Exercisable, December 31, 2017       14,699,582                          
                                   
Granted       286,875           $ 0.40       4.92  
                                   
Exercised                            
                                   
Forfeited                            
                                   
Expired       (124,533 )         $ 0.90          
                                   
Outstanding, June 30, 2018       14,861,924             $ 0.11       5.04  
                                   
Exercisable, June 30, 2018       14,861,924             $ 0.11       5.04  

 

NOTE 9 ASSET PURCHASE

 

NHS Holdings, LLC

 

The Company issued 27,769,500 shares of its restricted common stock valued at approximately $972,000 based on the closing price of the Company’s common stock on April 18, 2018 in exchange for certain assets of NHS Holdings, LLC (NHS), the exclusive U.S. distributorship of Vystar’s Vytex® virtually allergen-, VOC-, and odor-free natural rubber latex (NRL) foam. All shares of restricted common stock issued inconjuction with this transaction will be held in escrow for a minimum of six months to secure certain potential indemnification obligation of NHS. Such shares will be voted by NHS while they are held in escrow.

 

As the exclusive global distributor of Vytex® in the home furnishing goods market, NHS worked extensively with NRL producers to create Vytex® foam products for the bedding industry. NHS was instrumental in introducing these products to manufacturers for use in mattresses, pillows and other bedding products. In addition, NHS was the non-exclusive, global distributor of products in other industries utilizing the Vytex® NRL process. Reacquiring the Vytex® distribution rights from NHS is expected to stimulate sales by lowering the cost of Vytex® to the manufacturer as a result of eliminating the middleman which will allow the Company to realize the entire gross margin on the sale rather than a 7% royalty on the cost of the product to NHS previously provided in the distribution agreement.

 

  17  
 

 

The following summarizes the transaction with NHS Holdings, LLC at closing on April 18, 2018:

 

Cash   $ 15,000  
         
Inventory     203,591  
         
Property and equipment     22,000  
         
Intangible assets     731,341  
         
Total assets   $ 971,932  
         
Net purchase (fair value of common stock issued)   $ 971,932  

 

In determining the fair value of the intangible assets, the Company considered, among other factors, the best use of acquired assets such as the reacquired distribution rights, customer relationships, analysis of historical financial performance of the products and estimates of future performance of the products and intellectual properties acquired. The preliminary establishment of the allocation to identifiable intangible assets required extensive use of financial information and management’s best estimate of fair value. The Company has preliminarily recorded the purchase price of the identified intangible assets and is, if applicable, amortizing such assets over their estimated useful lives of five years. The Company is in the process of finalizing the purchase price allocation and this preliminary allocation is subject to adjustment. Accordingly, differences between these preliminary estimates and the final allocation to the intangible assets may occur and these differences could have a material impact on the accompanying financial statements.

 

NHS Related Parties

 

NHS’s largest membership interest owners are also major investors and in some cases affiliates and/or reporting insiders of the Company. NHS major shareholders include:

 

  Steven Rotman, President, CEO, and interim CFO of the Company and member of the Company’s Board of Directors
     
  Dr. Keith Osborn, MD; member of the Company’s Board of Directors, orthopedic spine surgeon;
     
  Dr. Bryan Stone, MD; member of the Company’s Board of Directors, nephrologists and CEO of Fluid Energy Conversion.

 

 

  18  
 

 

UV Flu Technologies, Inc.

 

Effective May 7, 2018, nine (9) shareholders of the Company, consented to purchase substantially all the assets of UV Flu Technologies, Inc., a Nevada corporation (“UV Flu”). The consents were submitted pursuant to Rule 14(a)-2(b) (2) promulgated under the Securities and Exchange Act of 1934, as amended. Such Rule provides that other than certain proxy solicitation rules which were either complied with or were otherwise not applicable to the consents submitted to the Company, the proxy solicitation rules set forth in SEC Regulation 14A do not apply to “[any] solicitation made otherwise than on behalf of the registrant where the total number of persons being solicited is not more than ten.” The Company has been presented with written consents which include (a) an approved form of Asset Purchase Agreement between the Company and UV Flu with respect to the purchase of substantially all the assets of UV Flu. The Common Stock held by the consenting shareholders totaled 118,211,379 shares or approximately 52.8% of the total outstanding shares of Common Stock of the Company.

 

Pursuant to the Asset Purchase Agreement, the purchase of substantially all assets of UV Flu was consummated on May 7, 2018. Vystar acquired all UV Flu intellectual property & two patents, product lines, tooling, FDA clearances, research data, websites and other assets for the purchase price of $1,814,670 or 27,918,000 shares of Vystar restricted common stock which may not be assigned or sold by UV Flu for twelve months. Vystar will continue production of UV Flu product lines with Blue Ocean Innovation, Ltd., a world-class manufacturer. We anticipate that the first container of product will be completed by the end of August and received into inventory by mid-September. Vystar plans to sell RxAir residential units via online and retail channels.

 

Vystar is assembling the distribution network to relaunch sales of UV400 and Rx3000 units to the healthcare and medical markets, which UV Flu had ceased due to sales force, distribution and cash flow constraints.

 

All shares of restricted common stock issued to UV Flu at closing will be held for a minimum of one year before sale or distribution of such shares to the UV Flu shareholders and will be voted consistent with the vote of the Company’s other shareholders until such distribution.

 

The following summarizes the transaction with UV Flu at closing on May 7, 2018:

 

Property and equipment   $ 319,000  
         
Intangible assets     1,495,670  
         
Total assets   $ 1,814,670  
         
Net purchase (fair value of common stock issued)   $ 1,814,670  

 

In determining the fair value of the intangible assets, the Company considered, among other factors, the best use of acquired assets such as tooling and testing equipment, analysis of historical financial performance of the products and estimates of future performance of the products and intellectual properties acquired. The fair values of the identified intangible assets related to the website, FDA Certification, Tradename and branding and the Company has preliminarily recorded the purchase price of the identified intangible assets and is amortizing such assets over their estimated useful lives ranging from 4 to 6 years. The Company is in the process of finalizing the purchase price allocation and this preliminary allocation is subject to adjustment. Accordingly, differences between these preliminay estimates and the final allocation to the intangible assets may occur and these differences could have a material impact on the accompanying financial statements.

 

The operations of UV Flu Technologies were not considered significant during the six months ended June 30, 2018.

 

NOTE 10 RELATED PARTY TRANSACTIONS

 

Designcenters.com

 

This entity is owned by Jamie Rotman, who is the daughter of the Company’s CEO, Steven Rotman. Design Centers provides bookkeeping services to the Company. In exchange for such services, the Company has entered into a consulting agreement with the related party entity (see Note 7).

 

Blue Oar Consulting, Inc.

 

This entity is owned by Gregory Rotman, who is the son of the Company’s CEO, Steven Rotman. Blue Oar provides business consulting services to the Company. In exchange for such services, the Company has entered into a consulting agreement with the related party entity (see Note 7).

 

CMA Investments, LLC

 

This entity has an outstanding note payable from the Company (See Note 6).

 

  19  
 

 

NOTE 11 SUBSEQUENT EVENTS

 

CMA Investments, LLC

 

The holders of CMA Investments, LLC, certain members of which are related parties to the Company, agreed, as of July 10, 2018, to change the terms of the debt as follows:

 

The Company will continue to service the debt for the next six months.
     

The Company issued 15 million shares in escrow which CMA could start to sell at the end of the six month period, noted above, at their discretion to bring down the debt over the next four years. In the event that the total value received upon the sale of the shares was less than the total obligation the Company shall either issue addditional shares or pay in cash the shortfall.
     

This debt is now considered long-term.

 

Peak One Opportunity Fund, L.P.

 

The Company entered into a financing agreement with Peak One Opportunity Fund, L.P. to receive $435,000 of Original issue discount notes in three issuances as follows:

 

1. July 17, 2018 principal $85,000 interest rate discounted by 10% and $5,000 for legal fees for a net of $71,500 due one year from the funding date. The Company has the option of receiving two additional amounts sixty days apart;
     

2. September 14, 2018 $150,000 principal $135,000 net;
     

3. November 13, 2018 a final $200,000 principal $180,000 net.

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

OVERVIEW

 

The foundations laid in the first quarter led to a very productive second quarter for Vystar. The company completed two asset purchases, keeping with management’s promise to grow through acquisitions, both of which will have a significant future positive impact on revenues. Vystar expanded retail and wholesale product offerings where higher margins exist, on the company’s patented Vytex latex.

 

The company added approximately one hundred new SKU’s in new density toppers as well as the new “Vytex Cloud” pillow line. In addition, the company made substantial headway on its new Bed-In-Box line “Symbol Vytex Cloud”. Management believes this product category will yield substantial new revenues and profits in the near and long term becoming a major revenue component of Vystar. The mattresses being produced in the USA will be ready for sale within the next few weeks. We are capable of high speed production and management sees no barrier to ramping sales. Management believes our product offerings in this category to be better priced and made of higher quality materials than any of the competition in this space, providing current and increased future revenues. The websites Vytexbed.com and Vytexcloud.com should be ready to launch in the next week and will include Vytex mattress toppers as well as our new pillows. We have also added some enhanced tools to our sites such as, integrated shipping and tracking software improving the customer’s experience. 

 

We made excellent progress on the “RXAIR” air purifiers, manufacturing is under way and the first of four containers will be shipping in the next few weeks. We made some modifications to the unit; higher quality bulbs, an additional upsell replacement cartridge that will last two years vs. one, and error checking software allowing us to better service our customers. The new RXAIR.com website is ready and a significant addition to our online sales intellectual property.

 

  20  
 

 

Management also spent considerable time and resources strengthening the balance sheet. Cash increased year over year from $63,000 to $414,000, inventories went from $0 to $508,000, total current assets increased from $155,000 to over $1,062,000. Management was successful with the help of major shareholders in eliminating $1.1 million in long term shareholder debt and an additional $1.5 million in other debt (listed as a subsequent event).  Revenues increased 1800% and gross profits were up 1200%. SGA and net loss grew due to the increase in staff and costs associated with the acquisitions and product development. 

 

During the second quarter the Company focused on shoring up the Vytex raw material supply and distribution chain, further announcements will be made near-term on these products and collaborations. Management also undertook an extensive review of its patent portfolio. Vystar’s Issued Patents include – 16 issued patents in 12 countries; 4 Issued U.S. Patents, 12 Issued Foreign Patents in 11 Countries; (1 Austria, 1 China, 1 Germany, 1 Guatemala, 1 Hong Kong, 2 India, 1 Indonesia, 1 Japan, 1 Malaysia, 1 South Africa, and 1 U.K.) We have additional patents pending in Thailand. This is a significant asset for Vystar and the company in concert with its attorneys are developing a strategy to stop infringement and expand licensing of our IP. Management believes Vytex is in a unique market position. To make cleaner virtually allergy free latex there are two other methods outside of Vytex; both are commercially much more expensive and lead to approximately a 30% loss of the important rubber content when compared to Vytex. This translates in a much weaker and more expensive product than Vytex.

 

RESULTS OF OPERATIONS

 

Comparison of the three months ended June 30, 2018 with the three months ended June 30, 2017

 

          Three Months Ended June 30,        
    2018     2017     $ Change     % Change  
          CONSOLIDATED        
Revenue, net   $ 59,029     $ 3,087     $ 55,942       1812.2 %
Cost of revenue     19,044       6,610       12,434       188.1 %
Gross profit (loss)     39,985       (3,523 )     43,508       1235.0 %
Operating expenses:                                
General and administrative     729,510       255,811       473,699       185.2 %
Total operating expenses     729,510       255,811       473,699       185.2 %
Loss from operations     (689,525 )     (259,334 )     (430,191 )     165.9 %
Other income     326,237             326,237       100.0 %
Interest (expense)     (61,302 )     (42,728 )     (18,574 )     43.5 %
Total other income (expense)     264,935       (42,728 )     307,663       720.1 %
                                 
Net loss   $ (424,590 )   $ (302,062 )   $ (122,528 )     40.6 %

 

  21  
 

 

Revenues

 

Revenues for the three months ended June 30, 2018 and 2017 from the Company were $59,029 and $3,087 respectively, for an increase of $55,942 or 1812.2%. The increase in revenues was due to the sale of Vytex foam toppers related to the asset purchase of NHS.

 

For the Company, gross profit/loss improved from a loss of ($3,523) for the period ended June 30, 2017 to a profit of $39,985 for the period ended June 30, 2018, an increase of $43,508 or 1,235%. Cost of revenue for the three months ended June 30, 2018 and 2017 was $19,044 and $6,610, respectively, an increase of $12,434 or 188.1%. The increase in cost of revenue was due to the cost of purchasing Vytex product.  

 

Operating Expenses

 

The Company’s operating expenses consist of general and administrative expenses. General and administrative expenses consist primarily of compensation and support costs for management and administrative staff, and for other general and administrative costs, including professional fees related to accounting, finance, and legal services as well as other operating expenses. The Company’s operating expenses were $729,510 and $255,811 for the three months ended June 30, 2018 and 2017, respectively, for an increase of $473,699 or 185.2%. These items included patents, latex consultants, accounting fees, employee expenses. This was the result of an increase in third-party contracted expenses and accounting fees, primarily to be paid-in stock compensation.

 

Other Income (Expense)

 

Other income (expense) for the three months ended June 30, 2018 consisted of interest expense of $61,302 and forgiveness of debt income of $326,237. This compares to net interest expense of $42,728 for the three months ended June 30, 2017. The forgiveness of debt income was derived from the conversion of shareholder notes to common stock and credits received on accrued professional fees.

 

Net Loss

 

Net loss was $424,590 and $302,062 for the three months ended June 30, 2018 and 2017, respectively, an increase of $122,528 or 40.6%. The increase in the net loss was primarily attributable to general and administrative expenses related to the stock-based compensation to consultants and employees from the management transition but was partially offset by the forgiveness of debt income.

 

  22  
 

 

Comparison of the six months ended June 30, 2018 with the six months ended June 30, 2017

 

          Six Months Ended June 30,        
    2018     2017     $ Change     % Change  
          CONSOLIDATED        
Revenue, net   $ 62,973     $ 6,323     $ 56,650       895.9 %
Cost of revenue     68,465       10,220       58,245       569.9 %
Gross loss     (5,492 )     (3,897 )     (1,595 )     40.9 %
                                 
Operating expenses:                                
General and administrative     2,492,959       536,592       1,956,367       364.6 %
Total operating expenses     2,492,959       536,592       1,956,367       364.6 %
                                 
Loss from operations     (2,498,451 )     (540,489 )     (1,957,962 )     362.3 %
                                 
Other income     326,237             326,237       100.0 %
Interest (expense)     (102,750 )     (85,271 )     (17,479 )     20.5 %
Total other income (expense)     223,487       (85,271 )     308,758       362.1 %
                                 
Net loss   $ (2,274,964 )   $ (625,760 )   $ (1,649,204 )     263.6 %

 

Revenues

 

Revenues for the six months ended June 30, 2018 and 2017 from the Company were $62,973 and $6,323 respectively, for an increase of $56,650 or 895.9%. The increase in revenues was due to the sale of Vytex foam toppers related to the asset purchase of NHS.

 

For the Company, gross loss increased from ($3,897) for the period ended June 30, 2017 to ($5,492) for the period ended June 30, 2018, an increase of $1,595. Cost of revenue for the six months ended June 30, 2018 and 2017 was $68,465 and $10,220, respectively an increase of $58,245 or 569.9%.

 

Operating Expenses

 

The Company’s operating expenses consist of general and administrative expenses. General and administrative expenses consist primarily of compensation and support costs for management and administrative staff, and for other general and administrative costs, including professional fees related to accounting, finance, and legal services as well as other operating expenses. The Company’s operating expenses were $2,492,959 and $536,592 for the six months ended June 30, 2018 and 2017, respectively, for an increase of $1,956,367 or 364.6%. These items included patents, latex consultants, accounting fees, employee expenses. This was the result of an increase in third-party contracted expenses and accounting fees, primarily to be paid-in stock compensation.

 

  23  
 

 

Other Income (Expense)

 

Other income (expense) for the six months ended June 30, 2018 consisted of interest expense of $102,750 and forgiveness of debt income of $326,237. This compares to net interest expense of $85,271 for the six months ended June 30, 2017. The forgiveness of debt income was derived from the conversion of shareholder notes to common stock and credits received on accrued professional fees.

 

Net Loss

 

Net loss was $2,274,964 and $625,760 for the six months ended June 30, 2018 and 2017, respectively, an increase of $1,649,204 or 263.6% in the net loss. The increase in the net loss was primarily attributable to the increase in general and administrative expenses related to the stock-based compensation to consultants and employees increased from the management transition.

 

LIQUIDITY AND CAPITAL RESOURCES

 

The Company’s financial statements are prepared using the accrual method of accounting in accordance with GAAP and have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities in the normal course of business.  However, the Company has incurred significant losses and experienced negative cash flow since its inception.  At June 30, 2018, the Company had cash of $414,363 and a deficit in working capital of $121,207.  Further, at June 30, 2018, the accumulated deficit amounted to $30,274,087.  As a result of the Company’s history of losses and financial condition, there is substantial doubt about the ability of the Company to continue as a going concern.

 

A successful transition to attaining profitable operations is dependent upon obtaining sufficient financing to fund the Company’s planned expenses and achieving a level of revenue adequate to support the Company’s cost structure. Management plans to finance future operations through the use of cash on hand, increased revenue from Vytex license fees, our credit facility, stock warrant exercises from existing shareholders, raising capital through private placements of capital stock and debt.

 

The Company’s future expenditures will depend on numerous factors, including: the rate at which the Company can introduce and license Vytex NRL to manufacturers; the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; market acceptance of the Company’s products and services; and competing technological developments. As the Company expands its activities and operations, cash requirements are expected to increase at a rate consistent with revenue growth after the Company has achieved sustained revenue generation.

 

There can be no assurances that the Company will be able to achieve its projected level of revenue in 2018 and beyond. If the Company is unable to achieve its projected revenue and is not able to obtain alternate additional financing of equity or debt, the Company would need to significantly reorient its operations, which could have a material adverse effect on the Company’s ability to achieve its business objectives and as a result may require the Company to file for bankruptcy or cease operations. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts classified as liabilities that might be necessary should the Company be forced to take any such actions.

 

  24  
 

 

Sources and Uses of Cash

 

For the six months ended June 30, 2018 and 2017, net cash used in operations was $694,189 and $344,728 respectively. The negative cash flow from operations for the six months ended June 30, 2018 resulted primarily from the net loss of $2,274,964 primarily attributable to our non-cash share-based compensation expense of $1,611,911. The negative cash flow for the six months ended June 30, 2017 resulted primarily from the net loss of $625,760, offset by non-cash charges related to non-cash share-based compensation expense of $214,502.

 

There was no cash investing activity during the six months ended June 30, 2018 and 2017.

 

Net cash provided by financing activities for the six months ended June 30, 2018 was $500,000 in proceeds from a loan from Fidelity Bank and $595,050, net in new loans from investors. Net cash provided by financing activities for the six months ended June 30, 2017 was $374,500 from the sale of common stock.

 

Off-Balance Sheet Arrangements

 

We do not have any off-balance sheet arrangements that may be reasonably likely to have a current or future material effect on our financial condition, liquidity, or results of operations.

 

DISCLOSURE REGARDING FORWARD-LOOKING STATEMENTS

 

Our Management’s Discussion and Analysis contains not only statements that are historical facts, but also statements that are forward-looking (within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934). Forward-looking statements are, by their very nature, uncertain and risky. These risks and uncertainties include international, national and local general economic and market conditions; demographic changes; our ability to sustain, manage, or forecast growth;  product development, introduction and acceptance; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; the ability to protect technology; and other risks that might be detailed from time to time in our filings with the Securities and Exchange Commission.

 

Although the forward-looking statements in this Quarterly Report reflect the good faith judgment of our management, such statements can only be based on facts and factors currently known by them. Consequently, and because forward-looking statements are inherently subject to risks and uncertainties, the actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. You are urged to carefully review and consider the various disclosures made by us in this report and in our other reports as we attempt to advise interested parties of the risks and factors that may affect our business, financial condition, and results of operations and prospects.

 

ITEM 3.         QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

None

 

  25  
 

 

ITEM 4.         CONTROLS AND PROCEDURES

 

The Company’s Chief Executive Officer and Chief Financial Officer (the Certifying Officer) is responsible for establishing and maintaining disclosure controls and procedures for the Company. Although the Certifying Officer has designed such disclosure controls and procedures to ensure that material information is made known to them, particularly during the period in which this report was prepared, certain material weaknesses occurred during the year ended June 30, 2018 and subsequent to year end. The Certifying Officer has evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e) (the Rules) under the Securities Exchange Act of 1934 (or Exchange Act) as of the end of the period covered by this Quarterly Report and is working on improving controls with an outside CPA firm and a more dedicated internal resources.

 

Management’s Report on Internal Control Over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d - 15(f) under the Securities Exchange Act of 1934). Internal control over financial reporting is a process to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. Internal control over financial reporting includes those policies and procedures that: (i) in reasonable detail accurately and fairly reflect our transactions; (ii) provide reasonable assurance that transactions are recorded as necessary for preparation of our financial statements; (iii) provide reasonable assurance that our receipts and expenditures are made in accordance with management authorization; and (iv) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on the financial statements.

 

Because of its inherent limitations, internal control over financial reporting, however well designed and operated, can provide only reasonable, and not absolute, assurance that the controls will prevent or detect misstatements. In addition, the design of any control system is based in part upon certain assumptions about the likelihood of future events. Because of these and other inherent limitations of control systems, there is only the reasonable assurance that our controls will succeed in achieving their goals under all potential future conditions.

 

Management, under the supervision and with the participation of our Chief Executive Officer and our Interim Chief Financial Officer, conducted an evaluation of our internal control over financial reporting as of June 30, 2018 based on the 2013 Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). Based on our evaluation under the COSO framework, management concluded that our internal control over financial reporting was not effective as of June 30, 2018. Such conclusion was reached based on the following material deficiencies noted by management :

 

a) We have a lack of segregation of duties due to the small size of the Company.

 

b) The Company did not maintain reasonable control over records underlying transactions necessary to permit preparation of the Company’s financial statements.

 

c) Lack of controls that provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposal of the Company’s assets that could have a material effect on the financial statements.

 

d) Lack of a formal CFO position who can devote significant attention to financial reporting resulted in multiple audit adjustments.

 

Management expects to strengthen internal control during 2018 by developing stronger business and financial processes for accounting for transactions such as warrant/stock issuances, which will enhance internal control for the Company.

 

  26  
 

 

PART II.  OTHER INFORMATION

 

ITEM 1.         LEGAL PROCEEDINGS

 

None

 

ITEM 2.         UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

Set forth below is information regarding shares of common stock, warrants and options to purchase common stock issued by the Company for the six months ended June 30, 2018, that were not registered under the Securities Act of 1933, as amended (the “Securities Act”). Also included is the consideration, if any, received by the Company for such shares, warrants and options and information relating to the section of the Securities Act, or rule of the Securities and Exchange Commission, under which exemption from registration was claimed.

 

(a)       Common Stock Financings

 

From December 31, 2017 through June 30, 2018 the Company issued:

 

24,449,979 shares in connection with consulting services at approximately $0.036 per share for $881,672,
     

27,918,000 shares in connection with the purchase of the assets of UV Flu at $0.065 per share for $1,814,670,
     

27,769,500 shares in connection with the purchase of the assets of NHS at $0.035 per share for $971,932,
     

22,686,375 shares in connection with the conversion of various shareholder loans at approximately $0.035 per share for $794,023,

 

(b)       Stock Option Grants

 

None during the period.

 

(c) Application of Securities Laws and Other Matters

 

No underwriters were involved in the foregoing sales of securities. The securities described in section (a) of this Item 2 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section 4(2) under the Securities Act and Regulation D promulgated thereunder, as applicable, relative to sales by an issuer not involving any public offering, to the extent an exemption from such registration was required.

 

All of the foregoing securities are deemed restricted securities for purposes of the Securities Act. All certificates representing the issued shares of common stock, warrants and options described in this Item 2 included appropriate legends setting forth that the securities had not been registered and the applicable restrictions on transfer.

 

ITEM 3.         DEFAULTS UPON SENIOR SECURITIES

 

 None

 

  27  
 

 

ITEM 4.         MINE SAFETY DISCLOSURES

 

 Not applicable

 

ITEM 5.         OTHER INFORMATION

 

 None

 

ITEM 6.         EXHIBITS

 

Exhibit Index

 

Number   Description
     
31.1 *   Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
31.2 *   Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
     
32.1 *   Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

101.INS   XBRL Instance Document
     
101.SCH   XBRL Taxonomy Extension Schema Document
     
101.CAL   XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF   XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB   XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE   XBRL Taxonomy Extension Presentation Linkbase Document

 

* Filed herewith.

 

  28  
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  VYSTAR CORPORATION
   
Date:  August 20, 2018 By: /s/ Steven Rotman
    Steven Rotman
    President, Chief Executive Officer, Interim Chief Financial Officer and Director

 

  29  

Vystar Corp. (QB) (USOTC:VYST)
Historical Stock Chart

1 Year : From Nov 2018 to Nov 2019

Click Here for more Vystar Corp. (QB) Charts.

Vystar Corp. (QB) (USOTC:VYST)
Intraday Stock Chart

Today : Tuesday 12 November 2019

Click Here for more Vystar Corp. (QB) Charts.

Latest VYST Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.